1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > CREABILIS Therapeutics S.r.l. - Product Pipeline Review - 2013

CREABILIS Therapeutics S.r.l. - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 25 pages

CREABILIS Therapeutics S.r.l. - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “CREABILIS Therapeutics S.r.l. - Product Pipeline Review - 2013” provides data on the CREABILIS Therapeutics S.r.l.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, CREABILIS Therapeutics S.r.l.’s corporate website, SEC filings, investor presentations and featured press releases, both from CREABILIS Therapeutics S.r.l. and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- CREABILIS Therapeutics S.r.l. - Brief CREABILIS Therapeutics S.r.l. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of CREABILIS Therapeutics S.r.l. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of CREABILIS Therapeutics S.r.l. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the CREABILIS Therapeutics S.r.l.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate CREABILIS Therapeutics S.r.l.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of CREABILIS Therapeutics S.r.l. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the CREABILIS Therapeutics S.r.l.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with CREABILIS Therapeutics S.r.l..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of CREABILIS Therapeutics S.r.l. and identify potential opportunities in those areas.

Table Of Contents

CREABILIS Therapeutics S.r.l. - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
CREABILIS Therapeutics S.r.l. Snapshot 4
CREABILIS Therapeutics S.r.l. Overview 4
Key Information 4
Key Facts 4
CREABILIS Therapeutics S.r.l. - Research and Development Overview 5
Key Therapeutic Areas 5
CREABILIS Therapeutics S.r.l. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
CREABILIS Therapeutics S.r.l. - Pipeline Products Glance 9
CREABILIS Therapeutics S.r.l. Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
CREABILIS Therapeutics S.r.l. - Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
CREABILIS Therapeutics S.r.l. - Drug Profiles 12
CT-327 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
CT-340 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
CT-637 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
CREABILIS Therapeutics S.r.l. - Pipeline Analysis 16
CREABILIS Therapeutics S.r.l. - Pipeline Products by Therapeutic Class 16
CREABILIS Therapeutics S.r.l. - Pipeline Products by Route of Administration 18
CREABILIS Therapeutics S.r.l. - Pipeline Products By Mechanism of Action 19
CREABILIS Therapeutics S.r.l. - Recent Pipeline Updates 20
CREABILIS Therapeutics S.r.l. - Dormant Projects 22
CREABILIS Therapeutics S.r.l. - Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25

List of Tables


CREABILIS Therapeutics S.r.l., Key Information 4
CREABILIS Therapeutics S.r.l., Key Facts 4
CREABILIS Therapeutics S.r.l. - Pipeline by Indication, 2013 6
CREABILIS Therapeutics S.r.l. - Pipeline by Stage of Development, 2013 7
CREABILIS Therapeutics S.r.l. - Monotherapy Products in Pipeline, 2013 8
CREABILIS Therapeutics S.r.l. - Phase II, 2013 9
CREABILIS Therapeutics S.r.l. - Phase I, 2013 10
CREABILIS Therapeutics S.r.l. - Pre-Clinical, 2013 11
CREABILIS Therapeutics S.r.l. - Pipeline By Therapeutic Class, 2013 17
CREABILIS Therapeutics S.r.l. - Pipeline By Route of Administration, 2013 18
CREABILIS Therapeutics S.r.l. - Pipeline Products By Mechanism of Action, 2013 19
CREABILIS Therapeutics S.r.l. - Recent Pipeline Updates, 2013 20
CREABILIS Therapeutics S.r.l. - Dormant Developmental Projects,2013 22

List of Figures


CREABILIS Therapeutics S.r.l. - Pipeline by Indication, 2013 6
CREABILIS Therapeutics S.r.l. - Pipeline by Stage of Development, 2013 7
CREABILIS Therapeutics S.r.l. - Monotherapy Products in Pipeline, 2013 8
CREABILIS Therapeutics S.r.l. - Pipeline By Therapeutic Class, 2013 16
CREABILIS Therapeutics S.r.l. - Pipeline Products By Mechanism of Action, 2013 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.